Modern medical management of obesity: The role of pharmaceutical intervention

Journal of the American Dietetic Association

Volumn 98, Issue 10 SUPPL. 2, 1998, Pages

  Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHEN FEN; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

AUTONOMIC NERVOUS SYSTEM; BODY WEIGHT; CHRONIC DISEASE; DRUG EFFECT; ENERGY EXPENDITURE; FAT INTAKE; FOOD INTAKE; HORMONAL REGULATION; HUMAN; OBESITY; REVIEW;

EID: 0031785696     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8223(98)00706-8     Document Type: Article

References (14)

1. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; Preprint June 1998.
2. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621-628.
3. Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA. 1996;276:1907-1915.
4. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine. US Dept of Health and Human Services interim public health recommendations. MMWR Morb Mortal Wkly Rep. 1997;(46):1.
5. Connolly H, Crary J, McGoon M, Hensrud D, Edwards B, Edwards W, Schaff H. Valvular heart disease associated with fenfluramine-phentermine [see comments]. N Engl J Med. 1997;337:581-588.
6. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes. 1993;17:241-244.
7. Stock M. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997;21(suppl 1):S25-S29.
8. Lean M. Sibutramine - a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997;21(suppl 1):S30-S36; discussion 37-9.
9. Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diab Rev. 1997;5:83-103.
10. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee Review of New Drug Application for Sibutramine. Washington, DC: US Government Printing Office; Sept. 26, 1996.
11. James W, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord. 1997;21(suppl 3):S24-S30.
12. Pi-Sunyer F, Mendel C, Seaton TB, Rowe E. Effect of Sibutramine (Meridia) on serum lipids: meta-analysis of 11 placebo-controlled trials [abstract]. Obesity Res. 1997;5(suppl 1):S30.
13. Hollander PA, Elbein SC, Hirsch IB, Kelley d, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. The role of orlistat in the treatment of obese patients with type 2 diabetes mellitus: a 1-year, randomized, double-blind study. Diabetes Care. 1998;21:1288-1294.
14. Food and Drug Administration. Endocrinologic and Metabolic Drug Advisory Committee Review of New Drug Application for Orlistat. Washington, DC: US Government Printing Office; May 14,1997.